Transportation of cellular therapy products: report of a survey by the cellular therapies team of the Biomedical Excellence for Safer Transfusion (BEST) collaborative

Vox Sang. 2010 Aug 1;99(2):168-73. doi: 10.1111/j.1423-0410.2010.01329.x. Epub 2010 Mar 10.

Abstract

Background and objectives: Most cell therapy products (CTP) are infused or processed shortly after collection but in some cases this may be delayed for up to 48 h. A number of variables such as temperature and cell concentration are of critical importance for the integrity of CTP during this time.

Materials and methods: We conducted a survey of cellular therapy laboratories to ascertain current practices for CTP transportation.

Results: There were 194 respondents of whom 90% shipped or received CTP--84% allogeneic, 71% autologous and 62% therapeutic cells. Processing facilities shipped or received the following products--hematopoietic progenitor cells (HPC), Marrow 73%; HPC, Apheresis 90%; HPC, Cord Blood 54% and others 14%. Other CTP included donor lymphocytes, mesenchymal stem cells (MSC), natural killer cells, buffy coat neutrophils and virus-specific cytotoxic T lymphocytes (CTL). More than 70% of respondents believed that it was acceptable for CTP to be held for up to 2 h without checking the temperature or cell density and a similar proportion agreed that putting products in containers to control parameters such as temperature within this time period was unnecessary. The majority of centres shipped or received between 1 and 10 CTP annually and 66% received products taking more than 2 h to ship. Of these, 82% specified the conditions for temperature in transit whilst 57% monitored temperature in transit and 74% of these used a data logger. The temperature range most commonly specified was 18-24 degrees C. The majority of processing facilities did not request an adjustment to the cell density even for products taking more than 2 h to reach their facility. More than 90% of respondents tested HPC for CD34(+) cells, viability and sterility; 40-48% performed colony-forming unit-granulocyte macrophage (CFU-GM) analysis. Only viability was thought by > 50% of respondents to be impacted by temperature, cell density and other parameters.

Conclusion: Understanding current practice will help in the design of future studies for CTP storage and transportation.

MeSH terms

  • Antigens, CD34 / chemistry
  • Biological Therapy / methods*
  • Biological Therapy / standards
  • Blood Preservation / methods
  • Blood Preservation / standards
  • Cell Transplantation / methods
  • Cell Transplantation / standards
  • Data Collection
  • Hematopoietic Stem Cells / cytology
  • Humans
  • Internet

Substances

  • Antigens, CD34